{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Regimen&page=4", "query": { "intervention": "Chemotherapy Regimen", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 8180, "total_pages": 818, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Regimen&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Chemotherapy+Regimen&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-05T23:44:52.912Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07169851", "title": "A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Nausea", "Vomiting", "Drug-Related Side Effects and Adverse Reactions", "Neoplasms" ], "interventions": [ { "name": "LY3537021", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Standard of Care Antiemetic Therapies", "type": "DRUG" }, { "name": "Background Chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 204, "start_date": "2025-11-28", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-09-04", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 21, "location_summary": "Greenbrae, California • Irvine, California • Los Alamitos, California + 18 more", "locations": [ { "city": "Greenbrae", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Alamitos", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Fort Collins", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT07169851" }, { "nct_id": "NCT03324802", "title": "Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Breast Cancer AJCC v7", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage II Breast Cancer AJCC v6 and v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7" ], "interventions": [ { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 107, "start_date": "2018-02-07", "completion_date": "2023-08-28", "has_results": true, "last_update_posted_date": "2024-05-02", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03324802" }, { "nct_id": "NCT00536601", "title": "High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET)", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Plasma Cell Neoplasm", "Primary Systemic Amyloidosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Malignant Testicular Germ Cell Tumor", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Neuroblastoma", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Multiple Myeloma", "Regional Neuroblastoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific", "Unspecified Childhood Solid Tumor, Protocol Specific", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "etoposide", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "thiotepa", "type": "DRUG" }, { "name": "total-body irradiation", "type": "RADIATION" }, { "name": "autologous hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "autologous-autologous tandem hematopoietic stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": null, "sex": "ALL", "summary": "4 Years and older" }, "enrollment_count": 174, "start_date": "2006-06-29", "completion_date": "2018-07-09", "has_results": true, "last_update_posted_date": "2021-04-22", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00536601" }, { "nct_id": "NCT06788912", "title": "Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Neoplasm Malignant" ], "interventions": [ { "name": "Pembrolizumab (neoadjuvant)", "type": "BIOLOGICAL" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Sacituzumab tirumotecan", "type": "DRUG" }, { "name": "H1 receptor antagonist", "type": "DRUG" }, { "name": "H2 receptor antagonist", "type": "DRUG" }, { "name": "Acetaminophen (or equivalent)", "type": "DRUG" }, { "name": "Dexamethasone (or equivalent)", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pembrolizumab (adjuvant)", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Steroid mouthwash (dexamethasone or equivalent)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-03-20", "completion_date": "2032-02-06", "has_results": false, "last_update_posted_date": "2026-09-28", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 9, "location_summary": "Daphne, Alabama • Santa Barbara, California • Lone Tree, Colorado + 5 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Santa Barbara", "state": "California" }, { "city": "Lone Tree", "state": "Colorado" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06788912" }, { "nct_id": "NCT00028028", "title": "CCI-779 in Treating Patients With Extensive-Stage Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "temsirolimus", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-28", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028028" }, { "nct_id": "NCT00054665", "title": "PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Lymphoma" ], "interventions": [ { "name": "PS-341", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2003-02", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2012-09-11", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 2, "location_summary": "Bethesda, Maryland • Buffalo, New York", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054665" }, { "nct_id": "NCT04310007", "title": "Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma", "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma", "Stage IV Lung Cancer AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cabozantinib S-malate", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2020-07-13", "completion_date": "2027-03-31", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 611, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 392 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04310007" }, { "nct_id": "NCT04735471", "title": "A Phase 1 Study of ADI-001 in B Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Follicular", "Lymphoma, Mantle-Cell", "Marginal Zone Lymphoma", "Primary Mediastinal B-cell Lymphoma", "Diffuse Large B Cell Lymphoma", "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "ADI-001", "type": "GENETIC" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "GENETIC", "DRUG" ], "sponsor": "Adicet Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2021-03-04", "completion_date": "2025-02-03", "has_results": false, "last_update_posted_date": "2025-06-18", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 10, "location_summary": "Stanford, California • Miami, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04735471" }, { "nct_id": "NCT06777979", "title": "CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent B Acute Lymphoblastic Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "CD19-CD22 CAR T cell infusion", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 30, "start_date": "2025-04-28", "completion_date": "2031-01", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06777979" }, { "nct_id": "NCT00858403", "title": "Dasatinib in Advanced Non-small Cell Lung Cancer (NSCL) With Ex Vivo and In Vivo Assessment of Tumor Target Modulation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-03", "completion_date": "2010-07", "has_results": true, "last_update_posted_date": "2014-01-15", "last_synced_at": "2026-10-05T23:44:52.912Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00858403" } ] }